Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Portfolio Pulse from Benzinga Newsdesk
Achilles Therapeutics reported a Q4 EPS loss of $(0.46), missing the consensus estimate of $(0.14) by 228.57%. Despite this, their cash position of $131.5M is expected to support operations through 2025. This represents a 24.59% improvement over the previous year's $(0.61) per share loss.
April 04, 2024 | 10:46 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Achilles Therapeutics reported a larger than expected Q4 EPS loss but has a strong cash position to support future operations.
The significant miss in EPS expectations could lead to short-term negative sentiment among investors, despite the company's solid cash position indicating long-term operational security.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100